Cardiovascular profile of loratadine.
The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.
Hey
J A
JA
Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.
Affrime
M
M
Cobert
B
B
Kreutner
W
W
Cuss
F M
FM
D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects*; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; D004347:Drug Interactions; D000072237:ERG1 Potassium Channel; D004562:Electrocardiography / Q000187:drug effects; D051638:Ether-A-Go-Go Potassium Channels; D006634:Histamine H1 Antagonists / Q000009:adverse effects*; D006801:Humans; D017336:Loratadine / Q000009:adverse effects*; D015221:Potassium Channels / Q000187:drug effects; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG
D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; C072312:ERG protein, human; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006634:Histamine H1 Antagonists; C092509:KCNH6 protein, human; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; D017336:Loratadine